

Vaccines, Variants, IHME model

- Table 3. The SEIR model uses variant-specific estimates of vaccine efficacy at preventing symptomatic disease and at preventing infection. We use data from clinical trials directly, where available, and make estimates otherwise. More information can be found on our website (<http://www.healthdata.org/node/8584>).
- IHME. COVID-19 Results Briefing. Iran (Islamic Republic of). May 21, 2021
- https://www.healthdata.org/sites/default/files/covid_briefs/142_briefing_Iran_Islamic_Republic_of.pdf
- This file May 23, 2021

Table 3. The SEIR model uses variant-specific estimates of vaccine efficacy at preventing symptomatic disease and at preventing infection. We use data from clinical trials directly, where available, and make estimates otherwise. More information can be found on our website (<http://www.healthdata.org/node/8584>).

Vaccine	Efficacy at preventing disease: D614G & B.1.1.7	Efficacy at preventing infection: D614G & B.1.1.7	Efficacy at preventing disease: B.1.351, B.1.617, & P.1	Efficacy at preventing infection: B.1.351, B.1.617, & P.1
AstraZeneca	74%	52%	10%	9%
CoronaVac	50%	44%	38%	33%
Covaxin	78%	69%	59%	52%
Janssen	72%	72%	64%	56%
Moderna	94%	89%	79%	75%
Novavax	89%	79%	49%	43%
Pfizer/BioNTech	91%	86%	76%	72%
Sinopharm	73%	65%	55%	49%
Sputnik-V	92%	81%	70%	61%
Tianjin	66%	58%	50%	44%
CanSino				
Other vaccines	75%	66%	57%	50%
Other vaccines (mRNA)	91%	86%	76%	72%

>

>

>

>

>

Original sort				
Vaccine	Old, UK Symptomatic	Old, UK Infection	AFR, UK, BRA Symptomatic	AFR, UK, BRA Infection
AstraZeneca	74	52	10	9
CoronaVac	50	52	38	33
Covaxin	78	69	59	52
Janssen	72	72	64	56
Moderna	94	89	79	75
Novavax	89	79	49	43
Pfizer/BioNTech	91	86	76	72
Sinopharm	73	65	55	49
Sputnik-V	92	81	70	61
Tianjin CanSino	66	58	50	44
Other vaccines	75	66	57	50
Other (mRNA)	91	86	76	72

	Sorted by:			
Vaccine	Old, UK Symptomatic	Old, UK Infection	AFR, UK, BRA Symptomatic	AFR, UK, BRA Infection
Moderna	94	89	79	75
Sputnik-V	92	81	70	61
Pfizer/BioNTech	91	86	76	72
Other (mRNA)	91	86	76	72
Novavax	89	79	49	43
Covaxin	78	69	59	52
Other vaccines	75	66	57	50
AstraZeneca	74	52	10	9
Sinopharm	73	65	55	49
Janssen	72	72	64	56
Tianjin CanSino	66	58	50	44
CoronaVac	50	52	38	33

		Sorted by:		
Vaccine	Old, UK Symptomatic	Old, UK Infection	AFR, UK, BRA Symptomatic	AFR, UK, BRA Infection
Moderna	94	89	79	75
Pfizer/BioNTech	91	86	76	72
Other (mRNA)	91	86	76	72
Sputnik-V	92	81	70	61
Novavax	89	79	49	43
Janssen	72	72	64	56
Covaxin	78	69	59	52
Other vaccines	75	66	57	50
Sinopharm	73	65	55	49
Tianjin CanSino	66	58	50	44
AstraZeneca	74	52	10	9
CoronaVac	50	52	38	33

			Sorted by:	
Vaccine	Old, UK Symptomatic	Old, UK Infection	AFR, UK, BRA Symptomatic	AFR, UK, BRA Infection
Moderna	94	89	79	75
Pfizer/BioNTech	91	86	76	72
Other (mRNA)	91	86	76	72
Sputnik-V	92	81	70	61
Janssen	72	72	64	56
Covaxin	78	69	59	52
Other vaccines	75	66	57	50
Sinopharm	73	65	55	49
Tianjin CanSino	66	58	50	44
Novavax	89	79	49	43
CoronaVac	50	52	38	33
AstraZeneca	74	52	10	9

				Sorted by:
Vaccine	Old, UK Symptomatic	Old, UK Infection	AFR, UK, BRA Symptomatic	AFR, UK, BRA Infection
Moderna	94	89	79	75
Pfizer/BioNTech	91	86	76	72
Other (mRNA)	91	86	76	72
Sputnik-V	92	81	70	61
Janssen	72	72	64	56
Covaxin	78	69	59	52
Other vaccines	75	66	57	50
Sinopharm	73	65	55	49
Tianjin CanSino	66	58	50	44
Novavax	89	79	49	43
CoronaVac	50	52	38	33
AstraZeneca	74	52	10	9